Severe neonatal hyperbilirubinemia and kernicterus: are these still problems in the third millennium?

Michael Kaplan1, Ruben Bromiker, Cathy Hammerman

  • 1Department of Neonatology, Shaare Zedek Medical Center, Jerusalem, Israel. kaplan@cc.huji.ac.il

Neonatology
|October 5, 2011
PubMed

Insights

Bilirubin encephalopathy and kernicterus remain significant threats to newborns, even in developed nations. Continued vigilance and improved management strategies are crucial to minimize this preventable brain damage.

Area of Science:

  • Neonatal Medicine
  • Pediatric Neurology

Background:

  • Bilirubin encephalopathy and kernicterus cause permanent brain damage in newborns.
  • These conditions persist globally, affecting both developing and developed countries.
  • Existing guidelines for jaundice detection and hyperbilirubinemia treatment have not eradicated the problem.

Purpose of the Study:

  • To review current aspects of bilirubin encephalopathy and kernicterus.
  • To highlight recent severe cases and discuss contributing factors.
  • To identify strategies for reducing bilirubin-related harm.

Main Methods:

  • Review of recent literature and case reports on severe hyperbilirubinemia and kernicterus.
  • Analysis of factors contributing to the persistence of these conditions.
  • Synthesis of current knowledge on management and prevention.

Main Results:

  • Severe hyperbilirubinemia and kernicterus continue to be reported worldwide.
  • Multiple factors contribute to the ongoing incidence of these conditions.
  • Effective strategies are needed to further reduce bilirubin-related morbidity and mortality.

Conclusions:

  • Bilirubin encephalopathy and kernicterus remain significant clinical challenges.
  • A comprehensive approach is necessary to address the multifactorial causes.
  • Further efforts are required to minimize and prevent bilirubin-induced neurological damage in neonates.

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...